Adenovir Pharma strengthens its patents for treatment of the serious and very contagious eye infection EKC

2018-07-03

Adenovir Pharma´s patent applications relating to its novel ”Multivalent sialic acid derivates compound” (APD-514) for treatment of the serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC), have been approved in several key markets: United States, Japan, EU and Australia.

For more information, please contact:
Björn Dellgren, CEO/project leader, Adenovir Pharma AB, bjorn.dellgren@adenovir.com, 
+46 (0)707 455 005